Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Down 55.6% in March

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 2,400 shares, a drop of 55.6% from the February 28th total of 5,400 shares. Based on an average daily trading volume, of 6,700 shares, the short-interest ratio is currently 0.4 days.

Santen Pharmaceutical Stock Down 0.8 %

Santen Pharmaceutical stock opened at $9.63 on Friday. Santen Pharmaceutical has a 52 week low of $8.65 and a 52 week high of $13.00. The stock has a 50-day moving average price of $9.59 and a 200 day moving average price of $10.69.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.